AIMSTM enables an innovative
biomarker led drug pipeline

Focusing on emerging drug targets, Protai's AIMSTM platform paves the way to a unique precision medicine approach, facilitating an accelerated drug development process
PRT-002 (KAT6)
PRT-003 (Immunology)
Multiple programs
in evaluation
STAGE
Discovery
Preclinical
IND Enabling

Collaborate with us

Our portfolio and pipeline assets extend from early discovery through to late preclinical and we are looking to engage with pharma companies with potential interest in partnering/licensing our assets.